GAITHERSBURG, Md. (EGMN) - A Food and Drug Administration advisory panel on Oct. 5 voted 10-0 that the benefit-to-risk profile of the angiogenesis inhibitor pazopanib for advanced renal cell carcinoma was acceptable, but strongly recommended close postmarketing surveillance of hepatoxicity in patients treated with the drug, if it is approved. At the meeting of the FDA's Oncologic Drugs Advisory Committee, panelists generally agreed that the drug was effective and would be a useful treatment for advanced...